Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUM-201
- Development stage
- Unknown
- Lead developer
- Sumaya Biotech
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
SUM-201 (also known as SC83288) is a small molecule antimalarial being developed by Sumaya Biotech for the treatment of severe malaria. It possesses a novel mechanism of action targeting the parasite's DNA and tRNAAsp methyltransferase, PfDNMT2, which links the drug's action to impaired epigenetic regulation. Designed as a potential second-line treatment to address increasing resistance against current therapies like artemisinin, SUM-201 is characterized by rapid parasite killing and a favorable safety margin. It is intended for intravenous administration, specifically targeting the asexual blood stages of Plasmodium falciparum.
Beyond the preview
Go deeper on SUM-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUM-201.